Blood pressure is the force of your blood pushing against the walls of your arteries. Each time your heart beats, it pumps blood into the arteries. Your blood pressure is highest when your heart beats, pumping the blood. This is called systolic pressure. When your heart is at rest, between beats, your blood pressure falls. This is called diastolic pressure.
Your blood pressure reading uses these two numbers. Usually the systolic number comes before or above the diastolic number. A reading of
119/79 or lower is normal blood pressure
140/90 or higher is high blood pressure
Between 120 and 139 for the top number, or between 80 and 89 for the bottom number is called preHypertension. PreHypertension means you may end up with high blood pressure, unless you take steps to prevent it.
High blood pressure usually has no symptoms, but it can cause serious problems such as stroke, heart failure, heart attack and kidney failure.
You can control high blood pressure through healthy lifestyle habits such as exercise and the DASH diet and taking medicines, if needed.
Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
The main outcome measurement will be the modified Rankin scale at 3 months after the SAH, compared between patients who were randomized to induced Hypertension and patients who were randomized to no induced Hypertension.; Related to treatment failure: proportion of patients in the induced Hypertension group in which induced Hypertension did not give clinical improvement of symptoms of DCI within 24 hours; Related to the functional condition: Case fatality 30 days after SAH; Related to the functional condition, activities of daily living (ADL), three months after the SAH assessed with the Barthel Index.; Related to the functional condition: quality of life, three months after the SAH, estimated with the Stroke Specific Quality of Life Scale (SSQoL-12-NL).; Related to the functional condition: anxiety and depression, three months after the SAH, assessed with the Hospital Anxiety and Depression Scale (HADS).; Related to the functional condition: cognitive functioning, three months after the SAH, evaluated by the Cognitive Failures Questionnaire (CFQ).; Related to adverse effects: complications related to insertion of a central venous catheter or intra-arterial catheter (including local haemorrhage and pneumothorax).; Related to adverse effects: intracranial complications related to induced Hypertension (such as exacerbation of cerebral oedema, hemorrhagic infarction and bleeding of an asymptomatic aneurysm).; Related to adverse effects~+mn~ • Systemic complications related to induced Hypertension (including cardiac rhythm disorders, low cardiac output state and cardiac ischemia).; In selected centres: Related to the influence on cerebral haemodynamics: the difference in CBF, CBV, TTP and MTT between the intervention and the control groups 24-36 hours after the start of the study (i.e. CTP-2); Related to the influence on cerebral haemodynamics: the difference in CBF, CBV, TTP and MTT between the perfusion CT-scan (at baseline, the moment of deterioration, i.e. CTP-1) and the second perfusion CT-scan (CTP-2) within the same patients.; Direct medical costs of used health care resources and indirect, non-medical costs of lost productivity, will be compared between the two arms of the trial, twelve months after the SAH.
Differences in Pulmonary Hypertension biomarkers in patients evaluated for Pulmonary Hypertension; Vasodilator-induced changes in Pulmonary Vascular Resistance (PVR); Vasodilator-induced changes in Pulmonary Hypertension biomarkers
Change in Hypertension knowledge, patient self-efficacy, and patient engagement in self management activities after 3 months, in the intervention group compared to the control group; Changes in blood pressure and antihypertensive medications
Immunological markers of prognosis interest in pulmonary arterial Hypertension (PAH); Target antigens of autoantibodies; Subpopulations of patients with PAH whose serum is able to induce the production of reactive oxygen species (ROS)
a statistically significant 12 mm Hg (or more) greater change of blood pressure in one group compared to the other; resolution of Hypertension (normal blood pressure, no drugs required); serious (disabling) adverse events attributable to Hypertension or its drug treatment
Drug: 20 mg sildenafil citrate by mouth; Drug: sodium tanshinone IIA sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth
mPAP by right heart catheterization; WHO functional class of pulmonary Hypertension(PH); Borg dyspnea score; Minnesota living with heart failure questionnaire; 6-minute walk distance (6MWD); Pulmonary vascular resistance(PVR) measured by right heart catheterization
Pulmonary Hypertension, Familial Persistent, of the Newborn
Drug: placebo; Drug: iv sildenafil
Time on inhaled nitric oxide treatment after initiation of iv study drug; Treatment failure rate, defined as need for additional treatment targeting persistent pulmonary Hypertension of the newborn.; Time to final weaning of mechanical ventilation for persistent pulmonary Hypertension of the newborn; Time from initiation of study drug to treatment failure; Change in oxygenation parameters at 6, 12, and 24 hours from baseline; Sildenafil plasma concentrations and corresponding PK parameters; Safety parameters: incidence and severity of adverse events and abnormal laboratory parameters
Prevalence of resistant Hypertension; Analysis of correlation in patients with resistant Hypertension and patients with controlled Hypertension who received triple antihypertensive therapy in terms of demography, clinical characteristics and other factors